



Corrigendum: Melatonin Protects MCAO-Induced Neuronal Loss via NR2A Mediated Prosurvival Pathways

Fawad Ali Shah^{1,2†}, Gongping Liu^{3,4†}, Lina T. Al Kury⁵, Alam Zeb², Phil-Ok Koh⁶, Muzaffar Abbas⁷, Tao Li⁸, Xifei Yang⁹, Fang Liu^{10,11}, Yuhua Jiang^{12*} and Shupeng Li^{1,10,11*}

¹ State Key Laboratory of Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China, ² Riphah Institute of Pharmaceutical Sciences, Riphah International University Islamabad, Islamabad, Pakistan, ³ Key Laboratory of Ministry of Education of China and Hubei Province for Neurological Disorders, Department of Pathophysiology, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ⁴ Co-innovation Center of Neuroregeneration, Nantong University, Nantong, China, ⁵ College of Natural and Health Sciences, Zayed University, Abu Dhabi, United Arab Emirates, ⁶ Department of Anatomy, College of Veterinary Medicine, Research Institute of Life Science, Gyeongsang National University, Jinju, South Korea, ⁷ Department of Pharmacy, Capital University of Science and Technology, Islamabad, Pakistan, ⁸ Department of Forensic Medicine, School of Medicine, Xi'an Jiaotong University, Xi'an, China, ⁹ Centre for Addiction and Mental Health, Campbell Research Institute, Toronto, ON, Canada, ¹⁰ Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ¹¹ Key Laboratory of Modern Toxicology of Shenzhen, Shenzhen Center for Disease Control and Prevention, Shenzhen, China, ¹² Cancer Centre, The Second Hospital of Shandong University, Jinan, China

OPEN ACCESS

Edited and reviewed by:
Frontiers in Pharmacology
Editorial Office,
Frontiers Media SA,
Switzerland

*Correspondence:

Yuhua Jiang
jiangyuhua@sdu.edu.cn
Shupeng Li
lisp@pkusz.edu.cn;
lishupeng76@gmail.com

†These authors have contributed
equally to this work.

Specialty section:

This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Pharmacology

Received: 16 May 2019

Accepted: 30 May 2019

Published: 21 June 2019

Citation:

Shah FA, Liu G, Al Kury LT,
Zeb A, Koh P-O, Abbas M, Li T,
Yang X, Liu F, Jiang Y and Li S
(2019) Corrigendum: Melatonin
Protects MCAO-Induced
Neuronal Loss via NR2A Mediated
Prosurvival Pathways.
Front. Pharmacol. 10:702.
doi: 10.3389/fphar.2019.00702

Keywords: melatonin, ischemic stroke, NMDA receptor, AMPA receptor, PI3K/AKT/GSK3 pathway

A corrigendum on

Melatonin Protects MCAO-Induced Neuronal Loss via NR2A Mediated Prosurvival Pathways
by Shah FA, Liu G, Al Kury LT, Zeb A, Koh P-O, Abbas M, Li T, Yang X, Liu F, Jiang Y and Li S (2019).
Front. Pharmacol. 10:297. doi: 10.3389/fphar.2019.00297

Phil-Ok Koh was not included as an author in the published article. The corrected Author Contributions Statement appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

AUTHOR CONTRIBUTIONS

FA and GL managed the experimental work. FA and GL performed surgery, western blot, morphological experiments; performed data analysis. AZ, P-OK, MA, LA, FL, TL, XY, YJ and SL supported the study, designed study, and wrote the manuscript. YJ and SL are the corresponding authors, reviewed and approved the manuscript and held all the responsibilities related to this manuscript. All authors reviewed and approved the manuscript.

Copyright © 2019 Shah, Liu, Al Kury, Zeb, Koh, Abbas, Li, Yang, Liu, Jiang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.